CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
E5202 | ECOG | A Randomized Phase III Study Comparing 5-FU; Leucovorin and Oxaliplatin Versus 5-FU; Leucovorin; Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers | Adult CIRB - Late Phase Emphasis | Available to Open |
A022004 | Alliance | Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
S0200 | SWOG | A Phase III Randomized Study of Pegylated Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients with Recurrent Epithelial Ovarian or Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy | Adult CIRB - Late Phase Emphasis | Completed |
A082101 | Alliance | Multimodality Therapy with Immunotherapy in Stage I-IIIA Sarcomatoid Mesothelioma | Adult CIRB - Late Phase Emphasis | Available to Open |
EA8143 | ECOG-ACRIN | A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) | Adult CIRB - Late Phase Emphasis | Available to Open |
A031704 | Alliance | PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] | Adult CIRB - Late Phase Emphasis | Available to Open |
NSABP-B-34 | NSABP | A Clinical Trial Comparing Adjuvant Clodronate Therapy vs. Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy | Adult CIRB - Late Phase Emphasis | Completed |
RTOG-0825 | RTOG | Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma | Adult CIRB - Late Phase Emphasis | Completed |
A091802 | Alliance | Phase II Randomized Trial of Avelumab Plus Cetuximab versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC) | Adult CIRB - Late Phase Emphasis | Available to Open |
NRG-HN011 | NRG | A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN) | Adult CIRB - Late Phase Emphasis | Available to Open |